RNAC Q3 2022 Earnings — Cartesian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RNACCartesian Therapeutics, Inc.

$216M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$21M-15.2% YoY

Gross Profit

$20M97.4% margin

Operating Income

-$2M-7.7% margin

Net Income

-$8M-38.1% margin

EPS (Diluted)

$-1.55

QoQ Revenue Growth

-47.3%

Cash Flow

Operating Cash Flow

$4M

Free Cash Flow

$4M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$178M

Total Liabilities

$93M

Stockholders' Equity

$85M

Cash & Equivalents

$113M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$21M	$24M	-15.2%
Gross Profit	$20M	$24M	-17.4%
Operating Income	-$2M	-$2M	+18.8%
Net Income	-$8M	-$18M	+55.9%